Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Revumenib
Other

Revumenib

Tracked across 1 events · 7 articles · First seen May 12, 2026 · Last active May 12, 2026

Sentiment
70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Tech
Syndax Revuforj Data at EHA 2026
Syndax Pharmaceuticals announced the release of 12 abstracts for its drug Revumenib (revumenib) that will be presented at the European Hematology Association (EHA) 2026 Congress. The abstracts highlight strong activity of Revumenib across various acute…
Impact: Revumenib (revumenib) is an FDA-approved menin inhibitor developed by Syndax Pharmaceuticals, with new clinical data highlighting its strong activity across various acute leukemia subtypes.
May 12, 2026 · 7 articles
Key Actions (2)
90 Revumenib showed strong activitySyndax Revuforj Data at EHA 2026
80 Revumenib showed compelling outcomesSyndax Revuforj Data at EHA 2026
NEWSDESK
Track Revumenib live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.